share_log

Chardan Capital Initiates Coverage On Prime Medicine With Buy Rating, Announces Price Target of $17

Chardan Capital Initiates Coverage On Prime Medicine With Buy Rating, Announces Price Target of $17

Chardan Capital以買入評級啓動對Prime Medicine的保險，宣佈目標股價爲17美元
Benzinga ·  04/22 19:49

Chardan Capital analyst Geulah Livshits initiates coverage on Prime Medicine (NASDAQ:PRME) with a Buy rating and announces Price Target of $17.

Chardan Capital分析師Geulah Livshits以買入評級啓動了對Prime Medicine（納斯達克股票代碼：PRME）的報道，並宣佈目標股價爲17美元。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論